Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Colon cancer testing and screening.

S R Hamilton1

  • 1Division of Pathology and Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. shamilto@mdanderson.org

Archives of Pathology & Laboratory Medicine
|October 28, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.

NPJ precision oncology·2022
Same author

Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

IRF4 and BATF are critical for CD8⁺ T-cell function following infection with LCMV.

Cell death and differentiation·2014
Same author

Expression of p27(Kip1) and bcl-2, cigarette smoking, and colorectal cancer risk.

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals·2013
Same author

A comparative study of the remodeling and integration of a novel AuNP-tissue scaffold and commercial tissue scaffolds in a porcine model.

Journal of biomedical materials research. Part A·2013
Same journal

Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease Sites.

Archives of pathology & laboratory medicine·2026
Same journal

Cross-Reactivity of TPIT Antibody Clone OTI2G1 in Chordoma: Structural Mechanisms and Diagnostic Implications.

Archives of pathology & laboratory medicine·2026
Same journal

Paracoccidioidomycosis at Autopsy: A Case Series and Literature Review.

Archives of pathology & laboratory medicine·2026
Same journal

Accuracy of Cytology Diagnosis for Well Differentiated Neuroendocrine Tumors: Assessment by the College of American Pathologists Non-Gynecologic Slide Program.

Archives of pathology & laboratory medicine·2026
Same journal

Serum Immunofixation Electrophoresis Guidance Conflict: A Call to Harmonize.

Archives of pathology & laboratory medicine·2026
Same journal

In Reply.

Archives of pathology & laboratory medicine·2026
See all related articles

Molecular testing can improve outcomes for patients with colorectal neoplasia through diagnosis and risk assessment. Future advancements will enable broader use in screening and surveillance, reducing cancer mortality.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Laboratory testing significantly impacts patient outcomes in neoplasia.
  • Molecular testing is crucial for diagnosing inherited syndromes related to colorectal neoplasia.
  • Current applications include identifying germline mutations in APC and DNA mismatch repair genes.

Purpose of the Study:

  • To review the current and future applications of laboratory testing in managing colorectal neoplasia.
  • To highlight the role of molecular testing in diagnosis, prognosis, and therapy prediction.
  • To discuss the technological advancements needed for broader implementation.

Main Methods:

  • Review of existing literature on laboratory and molecular testing in colorectal neoplasia.
  • Analysis of current diagnostic and characterization methods.

Related Experiment Videos

  • Discussion of future potential and technological requirements.

    • Main Results:

    • Molecular testing is established for diagnosing rare inherited colorectal cancer syndromes.
    • Prognostic and predictive molecular markers for colorectal tumors are nearing routine application.
    • Technological progress is essential for integrating molecular testing into general screening and high-risk surveillance.

    Conclusions:

    • Molecular methods are vital for improving patient outcomes in colorectal neoplasia.
    • Continued advancements will enhance the use of molecular testing in cancer management.
    • These methods are expected to contribute to a further decrease in colorectal cancer death rates.